Martin Dreyling

32.8k total citations · 4 hit papers
396 papers, 13.1k citations indexed

About

Martin Dreyling is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Martin Dreyling has authored 396 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Pathology and Forensic Medicine, 197 papers in Genetics and 193 papers in Oncology. Recurrent topics in Martin Dreyling's work include Lymphoma Diagnosis and Treatment (336 papers), Chronic Lymphocytic Leukemia Research (188 papers) and Viral-associated cancers and disorders (100 papers). Martin Dreyling is often cited by papers focused on Lymphoma Diagnosis and Treatment (336 papers), Chronic Lymphocytic Leukemia Research (188 papers) and Viral-associated cancers and disorders (100 papers). Martin Dreyling collaborates with scholars based in Germany, United States and France. Martin Dreyling's co-authors include Wolfgang Hiddemann, Emanuele Zucca, Michael Unterhalt, Eva Hoster, Bruce D. Cheson, Bertrand Coiffier, Randy D. Gascoyne, Joseph M. Connors, Anton Hagenbeek and Kensei Tobinai and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Martin Dreyling

378 papers receiving 12.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revised Response Criteria for Malignant Lymphoma

2007 3.2k citations Bertrand Coiffier, Martin Dreyling et al. Journal of Clinical Oncology profile →
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Eva Hoster, Martin Dreyling et al. Blood profile →
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

2020 324 citations Gilles Salles, Martin Dreyling et al. profile →
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →

Peers

Countries citing papers authored by Martin Dreyling

Since Specialization

Citations

This map shows the geographic impact of Martin Dreyling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Dreyling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Dreyling more than expected).

Fields of papers citing papers by Martin Dreyling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Dreyling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Dreyling. The network helps show where Martin Dreyling may publish in the future.

Co-authorship network of co-authors of Martin Dreyling

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Dreyling. A scholar is included among the top collaborators of Martin Dreyling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Dreyling. Martin Dreyling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B) 2024 ·Blood ·(unknown), Christian Schmidt, Marek Trněný, Eva Giné, Olivier Hermine, Anke Ohler, (unknown), (unknown), Eva Hoster, Christiane Pott, Martin Dreyling, Georg Heß	2
2	Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials 2024 ·Leukemia ·(unknown), Linmiao Jiang, Karol Pál, Peter J. Stewart, (unknown), Martin Schwarz, Wolfram Klapper, Stefan Alig, Nikos Darzentas, Hanneke C. Kluin‐Nelemans, Olivier Hermine, Martin Dreyling, David González de Castro, Eva Hoster, Christiane Pott, (unknown)	4
3	Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions 2024 ·Blood ·Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Philip A. Thompson, (unknown), Mathias Bressel, (unknown), Rodney J. Hicks, David Westerman, Stephen Lade, Christiane Pott, Rishu Agarwal, Rachel Koldej, David Ritchie, Martin Dreyling, Mark A. Dawson, Sarah‐Jane Dawson, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	7
4	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL 2023 ·American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, (unknown), Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	17
5	Follicular lymphoma: an update on biology and optimal therapy 2023 ·Leukemia & lymphoma ·(unknown), Martin Dreyling	2
6	Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus 2023 ·Hematological Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Julia Philippou‐Massier, Helmut Blum, (unknown), Martin Dreyling, (unknown)	0
7	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma 2022 ·Blood Advances ·Gilles Salles, Stephen J. Schuster, Martin Dreyling, (unknown), John Kuruvilla, Piers Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez Ubieto, Keith L. Davis, (unknown), Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thiéblemont, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Yucai Wang, Brian K. Link	26
8	Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia 2022 ·Infection ·(unknown), (unknown), Lars H. Lindner, Martin Dreyling, Michael von Bergwelt‐Baildon, Stefan Boeck, Clemens Gießen-Jung, Valeria Milani, Hans‐Joachim Stemmler, Marion Subklewe, Oliver Weigert, Karsten Spiekermann	1
9	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome 2021 ·Blood ·Lorenz Thurner, Natalie Fadle, Joerg Thomas Bittenbring, Evi Regitz, (unknown), (unknown), (unknown), (unknown), Niels Murawski, Viola Poeschel, Dominic Kaddu‐Mulindwa, Klaus‐Dieter Preuss, Stephan Stilgenbauer, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Sylvia Hartmann, Martin Dreyling, Christiane Pott, Moritz Bewarder, Eva Hoster	7
10	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study 2021 ·Blood ·Nathan Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, (unknown), Catherine Thiéblemont, Martin Dreyling, Stephen J. Schuster	4
11	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management 2020 ·Journal of Clinical Oncology ·Preetesh Jain, Martin Dreyling, John F. Seymour, Michael Wang	21
12	Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up 2019 ·Blood ·Simon Rule, Martin Dreyling, André Goy, Georg Heß, Rebecca Auer, Brad S. Kahl, José‐Ángel Hernández‐Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang	16
13	Impact of age on clinical risk scores in follicular lymphoma 2019 ·Blood Advances ·Stefan Alig, Vindi Jurinović, Alessandro Pastore, Sarah Haebe, Christian Schmidt, (unknown), Martin Dreyling, Michael Unterhalt, Eva Hoster, Wolfgang Hiddemann, Oliver Weigert	15
14	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network 2017 ·Blood ·Sietse Aukema, Eva Hoster, Andreas Rosenwald, (unknown), Marie‐Hélène Delfau‐Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke C. Kluin‐Nelemans, Olivier Hermine, Martin Dreyling, Wolfram Klapper	81
15	Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis 2017 ·Blood ·Simon Rule, Martin Dreyling, André Goy, Georg Heß, Rebecca Auer, Brad S. Kahl, José‐Ángel Hernández‐Rivas, Anil Londhe, Fong Clow, Sanjay Deshpande, Lori Parisi, Michael Wang	4
16	Mode of action of different PI3K-inhibitors in mantle cell lymphoma 2016 ·Haematologica ·Grit Hutter, Yvonne Zimmermann, (unknown), (unknown), (unknown), W. Hiddemann, Martin Dreyling	1
17	Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group 2014 ·Journal of Clinical Oncology ·Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Martin Dreyling, Michael Hallek, (unknown), Martin H. J. Wiesen, Mathias Witzens‐Harig, Lorenz Truemper, Ulrich Keller, Tanja Rixecker, Carsten Zwick, Niels Murawski	59
18	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study 2010 ·Journal of Clinical Oncology ·Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James M. Foran, Eva Giné, Christian Gisselbrecht, Nicolas Ketterer, Sunita D. Nasta, A. Z. S. Rohatiner, Ingo G.H. Schmidt‐Wolf, Martin Schüler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad	255
19	Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue 2008 ·Journal of Clinical Oncology ·Elena Hartmann, Verónica Fernández, Vı́ctor Moreno, Joan Valls, Luís Hernández, Francesc Bosch, Pau Abrisqueta, Wolfram Klapper, Martin Dreyling, Eva Hoster, Hans Konrad Müller‐Hermelink, German Ott, Andreas Rosenwald, Elı́as Campo	85
20	Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. 1996 ·PubMed ·Andrew Brenner, Abhaya Paladugu, Hui Wang, Olufunmilayo I. Olopade, Martin Dreyling, C. Marcelo Aldaz	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact